Table 1.

Patient characteristics and results of fluorescence in situ hybridization (FISH)

Sample	Patient #	Sex	Age	Disease duration (month)	Prior treatment	Time of TKI therapy (months)	Karyotype	34+/38− cells scored	I-FISH
07/028	1	m	59	228	IFN, IM, autologous SCT	77	46XY[20]	100	normal
07/031	2	f	64	36	IM, DAS	34	46XX[20]	67	del(7q) (9%)
07/061	5	m	47	96	IFN, IM, DAS, allogeneic SCT	84	46XY[20]	84	[+8 (1.2%)]
07/231	6	m	74	109	IM	89	46XY[20]	100	normal
07/246	7	f	66	29	IM, DAS	26	46XX[20]	21	normal
07/248	8	m	74	108	IM	89	46XY[20]	100	del(7q) (3%)
07/257	10	f	56	35	IM, DAS	30	46XX[20]	100	normal
07/263	11	f	80	166	IM	89	46XX[20]	17	+8 (76.5%)
07/279	12	m	72	84	IM	74	46XY[20]	100	normal
07/294	13	m	48	84	IM	80	46XY[20]	22	normal
07/299	14	m	51	84	IM	34	46XY[20]	100	normal
07/300	15	m	70	17	IM	75	XY,t(9;22;17)(q34;q11.2;q21)(1)/45,X,-Y(3)/46,XY(16)	12	−7 (16.7%)
07/315	16	m	57	96	IM, DAS	13	46XY[20]	100	normal
07/328	17	f	41	94	IM	86	46XX[20]	61	normal
07/329	18	f	49	34	IM, DAS	82	46XX[20]	103	normal
07/330	16	m	40	93	IM	30	46XY[20]	11	normal
07/344	17	f	63	54	IM, Ara-C	81	46XX[20]	6	normal
07/349	18	m	61	24	IM, NIL	60	46XY[20]	200	normal
08/001	19	m	72	70	IM, DAS, Ara-C, Arsenic trioxide	17	46XY[20]	15	normal

Ara-C – cytosine arabinoside; DAS – dasatinib; IFN – interferon-alpha; IM – imatinib; NIL – nilotinib; SCT – stem cell transplant